Use of sodium glucose cotransporter 2 (SGLT-2) inhibitor drugs to treat type 2 diabetes may also help to lower the risk of recurrent kidney stones and gout flare-ups, finds a study from Canada published by BMJ.
This article was originally published on MedicalXpress.com